Acupuncture Gains a Place in the Prediabetes Discussion
Prediabetes sits in a difficult clinical middle ground: not yet overt diabetes, yet far from benign. The condition carries rising global prevalence and meaningful cardiometabolic risk, while the tools used to define it still fail to align neatly across populations and assays. Fasting glucose, HbA1c, and postprandial glucose often tell slightly different stories, and those inconsistencies complicate both screening and treatment decisions. Against that backdrop, acupuncture and moxibustion have moved from tradition-centered practice into a more formal scientific conversation.
The review positions these interventions not as alternative curiosities, but as biologically plausible metabolic therapies. Their appeal rests on a disorder that is itself mechanistically layered: hepatic insulin resistance is prominent in impaired fasting glucose, skeletal muscle insulin resistance weighs more heavily in impaired glucose tolerance, and β-cell dysfunction progresses across both. Chronic low-grade inflammation, mitochondrial dysfunction, and lipotoxicity help drive the process, creating multiple targets that a multimodal intervention could theoretically influence at once.
A single-sentence clinical reality stands out: prediabetes is already a systemic disease before diabetes is diagnosed.
Metabolic Dysfunction Extends Beyond Glucose Numbers
The review describes prediabetes as a state shaped by tissue-specific insulin resistance and multi-organ crosstalk rather than by one isolated laboratory abnormality. That framing matters because it explains why a therapy with neuroendocrine effects could influence more than glucose excursions alone. In experimental and clinical contexts, acupuncture-related approaches have been linked to changes in insulin sensitivity, β-cell homeostasis, and signaling pathways tied to appetite and energy regulation.
Several mechanistic routes receive attention. The vago-islet axis may help regulate pancreatic secretion through autonomic signaling, while the hypothalamic-pituitary-adrenal axis offers another pathway through which stress biology can intersect with metabolic control. The review also points to leptin signaling modulation, a relevant target in a disorder where adiposity, inflammation, and endocrine feedback loops converge. These pathways do not offer a replacement for established lifestyle therapy, but they do provide a biologically coherent rationale for investigating acupuncture as an adjunct in early dysglycemia.
There is also an important translational point hidden inside the pathophysiology. Because prediabetes reflects dysfunction across liver, muscle, pancreas, and adipose tissue, interventions that influence autonomic tone and inflammatory signaling could plausibly create measurable metabolic effects even without direct pharmacologic receptor binding.
Clinical Evidence Favors Glucose and Insulin Resistance Improvements
Across randomized controlled trials and meta-analyses, acupuncture-related therapies have been associated with lower fasting blood glucose, lower postprandial glucose, and reductions in HbA1c. The review does not present a single unified protocol, but it does describe a repeated direction of effect across studies. Insulin resistance improved as well, which is clinically important because resistance often precedes overt hyperglycemia by years and remains one of the most actionable intermediate targets in prediabetes management.
The therapeutic menu includes more than one technique. Electroacupuncture appears repeatedly in the evidence base, but the review also discusses Zhuang medicine scraping combined with blood-letting and auricular acupoint embedding. These methods are not interchangeable, and the heterogeneity of protocols complicates direct comparison. Even so, the overall pattern suggests that acupuncture-related interventions can produce metabolic shifts strong enough to appear in standard glycemic endpoints.
Safety is described as favorable. No major safety concern emerges from the summary, and the review characterizes the interventions as low risk and scalable. In a condition where many patients do not meet thresholds for drug treatment but remain metabolically vulnerable, a safe adjunctive therapy has obvious appeal. The practical question is not whether glycemia matters; it is how to reduce progression without exposing large prediabetes populations to avoidable harm.
Neuroendocrine Regulation May Explain the Signal
One of the more compelling aspects of the review is its emphasis on mechanism rather than symptom relief alone. Acupuncture-related therapies may influence glucose handling through regulation of neuroendocrine circuits, which is consistent with the observed effects on insulin resistance and β-cell function. If autonomic balance improves pancreatic responsiveness and reduces stress-mediated dysregulation, then a treatment could produce modest but real effects across several metabolic readouts at once.
This is where the biological plausibility becomes useful at the bedside. Prediabetes is rarely a single-pathway disorder, so a therapy that acts through central and peripheral signaling may be able to engage multiple nodes in the disease network. The review’s discussion of mitochondrial dysregulation and chronic inflammation also fits that model. Improvements in inflammatory tone and cellular energy handling could help explain why clinical endpoints shift even in the absence of direct glucose-lowering drugs.
One sentence captures the therapeutic logic: a disorder built from overlapping defects may respond to an intervention that operates on overlapping control systems.
Methodologic Gaps Limit How Far the Evidence Can Be Pushed
The most persistent weakness in the field is not a lack of signal, but the quality and comparability of the studies generating it. The review identifies methodological heterogeneity, small sample sizes, and limited long-term follow-up as central problems. Those issues make it difficult to determine which acupuncture protocol is best, which patients benefit most, and whether the metabolic improvements persist beyond the intervention window.
Standardization remains a major unmet need. Without consistent treatment schedules, outcome definitions, and follow-up intervals, pooled interpretation becomes fragile. The diagnostic instability of prediabetes itself adds another layer of uncertainty, since different laboratory thresholds capture different patient groups. Inter-ethnic variability further complicates interpretation, especially when screening tools such as fasting glucose and HbA1c do not always agree.
The review argues for larger multicenter trials, standardized clinical protocols, and multi-omics mechanistic work. That combination would be necessary to move the field from plausible benefit to dependable clinical guidance. Until then, acupuncture and moxibustion remain promising adjuncts with supportive early evidence, but not yet a replacement for the core tools already used to identify and manage prediabetes.
What Future Trials Need to Answer
The next wave of research will need to determine whether the observed improvements translate into durable prevention of type 2 diabetes, not just short-term changes in glucose markers. It will also need to clarify dose, duration, and patient selection. The current evidence base suggests real metabolic activity, but the durability of benefit, the most responsive phenotypes, and the comparative value of different acupuncture-related methods remain unresolved.
Longer follow-up will matter because prediabetes is a chronic condition defined by progression risk over time. A therapy that nudges glucose and insulin resistance in the right direction for several weeks is useful only if those changes can be sustained. The review closes by pointing toward that unmet need: stronger trials, cleaner protocols, and deeper mechanistic work to establish whether acupuncture can occupy a stable place in prediabetes care rather than an experimental one.